Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

NCT05103683 is registered in ClinicalTrials.gov with TORL Biotherapeutics, LLC as lead sponsor.

NCT NCT05103683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer
Lead sponsor
TORL Biotherapeutics, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
November 17, 2021
Completion date
November 15, 2026
Enrollment
90 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, endometrial cancer, nsclc, ovarian cancer